Pharma Stocks: These 4 pharma companies have provided important business information, action will be taken in the stocks.:Four pharmaceutical companies have reported business information since the market closed on Friday.

News Topical, Digital Desk : Between Friday's market close and Saturday afternoon, news emerged regarding several pharmaceutical companies. These companies include Jubilant Pharma, Alkem Labs, Natco Pharma, and Zydus Lifesciences. Stocks of all these companies saw declines on Friday. New news may impact their stocks in the next session.

Jubilant Pharmova informed that the US FDA has classified the inspection of its manufacturing unit in Montreal, Canada as 'Official Action Indicated' (OAI). According to the company, this inspection was conducted as part of the same audit, which was reported in the report attached to CMO Montreal on November 4, 2025.
Jubilant Pharmova said that the unit is working closely with the US FDA to address the observations revealed in this audit. The news came on Saturday. Earlier, this pharma stock, part of the BSE 500 index, closed with a decline of more than 3 percent on Friday.

Alkem Laboratories Meanwhile, the USFDA has completed the pre-approval inspection of the manufacturing unit of Enzene Biosciences, associated with Alkem Laboratories. Following the inspection, the USFDA issued Form 483, recording a total of six procedural observations. However, the company clarified that Enzene received no observations on the data integrity front, which is considered a significant positive sign for its quality systems. Data integrity is considered a highly sensitive and critical parameter in the pharma sector. Shares of Alkem Laboratories, a BSE 200 index member, fell more than 7 percent on Friday before the news broke.

Natco Pharma Natco Pharma has received a key regulatory approval in India. The Hyderabad-based company has received permission from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic semaglutide injection in India. The company stated in an exchange filing that it plans to launch the product in the Indian market in March 2026. Prior to the announcement, shares of Natco Pharma, a BSE 500 index member, closed down more than 2 percent on Friday.

Zydus Lifesciences Ltd. has received final approval from the USFDA for Ammonium Lactate Cream, 12%. This cream is a topical prescription medication used to treat dry and scaly skin (xerosis) and ichthyosis vulgaris, a genetic skin condition. The announcement came after market hours on Friday. The BSE 200 stock closed down nearly 2 percent in the previous session.